The use of silymarin in the treatment of liver diseases

Drugs

Volumn 61, Issue 14, 2001, Pages 2035-2063

  Saller, R ^a   Meier, R ^b   Brignoli, R ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Tradyser GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; ALLOXAN; ALPHA INTERFERON; AMANITIN; ARACHIDONATE 5 LIPOXYGENASE; CHOLINESTERASE INHIBITOR; CISPLATIN; CYCLOSPORIN; DNA; FENTANYL; HALOTHANE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LAMIVUDINE; LEUKOTRIENE; LEUKOTRIENE B4; METHOTREXATE; NEUROLEPTIC AGENT; PARACETAMOL; PENICILLIN G; REACTIVE OXYGEN METABOLITE; RIBAVIRIN; SCAVENGER; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILYMARIN; UNINDEXED DRUG; VINCRISTINE; XENOBIOTIC AGENT;

ALCOHOL LIVER DISEASE; AMANITA PHALLOIDES; ASCITES; BRAIN DISEASE; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; DIABETES MELLITUS; DIGESTIVE SYSTEM HEMORRHAGE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SENSITIZATION; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MUSHROOM POISONING; NONHUMAN; REVIEW; SKIN ALLERGY; TOXIC HEPATITIS; VIRUS HEPATITIS;

AMANITA PHALLOIDES; BASIDIOMYCOTA; CIRSIUM; SILYBUM MARIANUM;

EID: 0035211762     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161140-00003     Document Type: Review

References (118)

1. Silymarinhaltige phytopharmaka. Biopharmazie als wesentliches therapeutisches Qualitätskriterium
2. A review of plants used in the treatment of liver disease: Part 1
3. Le traitement de l'hepatite alcoolique aigue
4. Pharma-clinics. Le medicament du mois. Le legalon (silymarine)
5. Milk thistle (Silybum marianum) for the therapy of liver disease
6. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments
7. The management of chronic hepatitis B infection
8. The treatment of chronic viral hepatitis
9. Global surveillance and control of hepatitis C
10. Chapter VII chronic hepatitis
11. Chapter 2. Meta-analisi: Generalità
12. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin
13. Silymarine during maintenance therapy of acute promyelocytic leukemia
14. Hepatoprotective and immunomodulatory effects of antioxidant therapy
15. Characterization of a transporting system in rat hepatocytes: Studies with competitive and non-competitive inhibitors of phalloidin transport
16. Silybin inhibition of amatoxin uptake in the perfused rat liver
17. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin
18. Inhibitory effect of silybin on the activity of 5-lipoxygenase of the porcine cerebral basilar artery
19. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells
20. Scavenging of reactive oxygen species by silibinin dihemisuccinate
21. Influence of tumor necrosis factor-alpha and silibin on the cytotoxic action of alpha-amanitin in rat hepatocyte culture
22. Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome P450 2El
23. Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis
24. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways
25. Antioxidants modulate acute solar ultraviolet radiation-induced NF- kappa-B activation in a human keratinocyte cell line
26. NF-kappa B-independent suppression of HIV expression by ascorbic acid
27. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis
28. Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats
29. Prevention of CCL4-induced liver cirrhosis by silymarin
30. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats
31. Effects of two bioflavonoids on certain cellular immune reactions in vitro
32. Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures
33. Inducers of cytochrome P450 2El enhance methotrexate-induced hepatocytoxicity
34. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity
35. Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Effects of diabetes
36. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin
37. Die mariendistel (Silybum marianum) und silymarin als lebertherapeutikum
38. Zur biologischen verfügbarkeit und verstoffwechselung von silybin
39. Löslichkeitsparameter von silybin, silydianin und silychristin
40. Bedeutung pflanzlicher begleitstoffe in extrakten
41. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats
42. Pharmacokinetic studies on IdB 1016, a sylibin-phosphatidylcholine complex, in healthy human subjects
43. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans
44. Nuovo complesso di inclusione tra silibina e la β-cyclodestrina: Velocita di dissoluzione in vitro in confronto a formulazioni tradizionali
45. Untersuchungen zum freisetzungsverhalten und zur bioäquivalenz von silymarin-präparaten
46. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidyl complex (silipide) in healthy volunteers
47. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay
48. Pharmacokinetic studies with silymarin in human serum and bile meth and find
49. Untersuchungen zur elimination von silymarin bei cholezystektomierten patienten. 1. Mitteilung: Biliäre und renale elimination nach einmaliger oraler gabe
50. Untersuchungen zur elimination von silymarin bei cholezystektomieren patienten. 2. Mitteilung: Biliäre elimination nach mehrfacher oraler gabe
51. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients
52. Ethanol elimination in man under influence of hepatoprotective silibinin
53. Silybin kinetics in patients with liver cirrhosis: Comparative study between silybin-phosphatidylcholine complex and silymarin
54. Pharmacokinetic study of silybin-phosphatidylcholin complex in liver cirrhosis after multiple doses
55. Treatment of mushroom poisoning
56. Treatment of Amanita mushroom poisoning: A review
57. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin
58. Prevention of silybin of phalloidin-induced acute hepatoxicity
59. Intoxicacion por setas tipo Amanita phalloides
60. Severe Vomiting, diarrhea (Clinical Conference)
61. Aminotransferase levels and silymarin in de novo tactine-treated patients with Alzheimer's disease
62. Postoperatives verhalten der serumcholinesterase und anderer leberenzyme
63. Therapeutic action of Silymarin on chronic hepatopathies caused by psychopharmaceuticals
64. Epatopatie tossiche professionali. Effetti terapeutici della silimarina
65. Protective effect of Legalon in workers exposed to organic solvents
66. The effect of silymarin on plasma levels of malon-dialdehyde in patients receinving longterm treatment with psychotropic drugs
67. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
68. Is liver fibrosis reversible?
69. Hepatitis C virus: Current understanding and prospects for future therapies
70. Ergebnisse zweier doppelblindstudien zur wirksamkeit von silymarin bei chronischer hepatitis
71. Zur behandlung der akuten virushepatitis mit silymarin. Ergebnisse einer kontrollierten studie
72. Zur wirkung von silymarin bei der behandlung der akuten virushepatitis. Ergebnis einer an zwei medizinischen zentren durchgefuhrten doppelblindstudie
73. Considerazioni sull'uso della silimarina e della SAMe nel trattamento dell'epatite infettiva acuta dell'infanzia
74. Cytoprotection in the nineties: Experience with ursodeoxycholic acid and silymarin in chronic liver disease
75. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis
76. Free radicals as mediators of alcohol toxicity
77. Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells
78. Silymarin (Legalon) kezeles hatasa idult alkoholos majbetegek antioxidans vedorendszerere es a lipid peroxidaciora (kettos vak protokoll)
79. Nachweis der therapeutischen wirksamkeit von legalon bei toxischen lebererkrankungen im doppelblindversuch
80. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study
81. Silymarin kezeles majvedo hatasa idult alkoholos majbetegsegben
82. Serum pro-collagen III peptide levels are related to lobular necrosis in untreated patients with chronic hepatitis C
83. Die therapie toxischer leberschäden mit legalon
84. Nutzen der medikamentösen lebertherapie in der hausäirztlichen praxis
85. Current treatment options in chronic hepatitis B Annual AGA Spring Postgraduate Course, Session II: Liver
86. Non-alcoholic steato-hepatitis
87. Prediction of one-year pretransplant survival in patients with cirrhosis
88. Care of patients with ascites
89. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
90. Traitement de l'hepatite alcoolique par la silymarine. Une etude comparative en double insu chez 116 malades
91. Estudio controlado sobre el efecto de la silimarina en la enfermedad hepatica alcoholica
92. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients
93. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial
94. Which patients with hepatitis C develop liver complications?
95. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis
96. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis
97. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection
98. An adverse reaction to the herbal medication milk thistle (Silybum marianum)
99. IgE- und IgG-Antikorper gegen flavonoide nach therapie mit flavonoidhaltigen medikamenten
100. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes
101. Milk thistle: Silybum marianum
102. Chapter 14. Epatite croniche
103. Evidence-based medicine and critical care